Find clinical trials for Eczema in Montréal, QC
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Eczema trials near Montréal, QC, CAN:
The purpose of this trial is to test if delgocitinib cream is effective at treating chronic hand eczema (CHE) and what side effects it may h...
Phase 3
Montreal, Canada and 39 other locations
The purpose of this study is to test if treatment with tralokinumab is safe and effectful to treat moderate-to-severe atopic hand eczema. Th...
Phase 3
Laval, Quebec, Canada and 60 other locations
the treatment of adults with moderate to severe Atopic Dermatitis (Eczema). OpSCF will be compared to a placebo.OpSCF or placebo will be adm...
Phase 2
Montréal, Quebec, Canada and 21 other locations
The purpose of this study is to evaluate the safety and tolerability of XmAb27564 following multiple doses among participants with plaque psoriasis a...
Phase 1
Montréal, Quebec, Canada and 7 other locations
The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate...
Phase 3
Montréal, Quebec, Canada and 179 other locations
The primary objective of the study is to assess the long-term safety of dupilumab in pediatric participants with AD.The secondary objectives of the s...
Phase 3
Montreal, Quebec, Canada and 83 other locations
/TCI, compared with placebo in combination with TCS/TCI at Week 24, assessed using Eczema Area and Severity Index (EASI)....
Phase 3
Montreal, Quebec, Canada and 234 other locations
This Phase 2a trial will evaluate the effects of EP262 in subjects with atopic dermatitis
Phase 2
Montréal, Quebec, Canada and 9 other locations
B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...
Phase 3
Montreal, Quebec, Canada and 557 other locations
This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.
Phase 3
Montreal, Quebec, Canada and 320 other locations
Clinical trials
Research sites
Resources
Legal